Boston Scientific Estimates Updated For 2010 And Beyond

Boston Scientific Corporation (NYSE: BSX) has reported solid 2Q results, with sales at $1.928B, coming in $17M above Street consensus. EPS showed at $0.12, one penny below J.P. Morgan's estimate, thanks to strong gross margin and lower operating expenses.

JPM projects EPS of $0.60 for the full year, with $0.13 expected for the 3Q. Revenue losses are expected to be around 4.6% for the year, and forecasts (according to JPM's growth model) BSX's revenues to grow 2.6% by mid 2012.

JPM maintains its "neutral" rating for BSX.

Boston Scientific Corporation closed yesterday at $5.87